Gilead Sciences, Inc. $GILD Shares Sold by Sprucegrove Investment Management Ltd.

Sprucegrove Investment Management Ltd. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 64.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 59,870 shares of the biopharmaceutical company's stock after selling 107,500 shares during the quarter. Gilead Sciences makes up approximately 0.9% of Sprucegrove Investment Management Ltd.'s holdings, making the stock its 10th largest holding. Sprucegrove Investment Management Ltd.'s holdings in Gilead Sciences were worth $7,348,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the business. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the third quarter worth $26,000. Financial Consulate Inc. grew its holdings in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares in the last quarter. North Star Investment Management Corp. increased its stake in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 86 shares during the last quarter. Finally, BOCHK Asset Management Ltd bought a new position in shares of Gilead Sciences in the fourth quarter valued at $31,000. Institutional investors own 83.67% of the company's stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. NASDAQ: GILD Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC restated a "buy" rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Barclays initiated coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an "equal weight" rating and a $155.00 price target on the stock. Daiwa Securities Group boosted their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. TD Cowen increased their price target on Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Finally, Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an "outperform" rating in a research report on Wednesday, February 18th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $157.35.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the insider directly owned 128,779 shares of the company's stock, valued at $18,152,687.84. This trade represents a 2.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares of the company's stock, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,640 shares of company stock worth $26,584,250 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $133.48 on Wednesday. The firm has a market capitalization of $165.68 billion, a P/E ratio of 19.72, a P/E/G ratio of 1.75 and a beta of 0.31. The firm's 50-day moving average price is $140.14 and its 200-day moving average price is $132.66. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The company's quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.